When do biologic drug patents expire and when will biosimilars launch?

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 5,750,104

Introduction

United States Patent 5,750,104, issued on May 5, 1998, represents a significant milestone within the realm of pharmaceutical patenting, particularly concerning novel drug compounds and therapeutic methods. This patent predominantly focuses on specific chemical entities with potential pharmacological applications, possibly within oncology or neurology, given industry trends during the patent's issuance timeframe. Analyzing both its claims and the surrounding patent landscape offers valuable insights into its strength, scope, and influence on subsequent innovation.

Overview of the Patent

Patent Summary:
Patent 5,750,104 claims a class of chemical compounds characterized by a particular molecular framework, involving structural modifications intended for enhanced biological activity. The patent emphasizes a core set of compounds with specific substituents, offering claims to both the compounds themselves and their uses in treating specific diseases, such as cancer or neurodegenerative disorders. The specification provides detailed synthetic routes, biological activity data, and potential therapeutic applications.

Field and Relevance:
Released during a period of active pharmaceutical innovation, this patent appears to occupy a critical position in the development of targeted therapies, notably within small molecule pharmaceuticals. Its scope encompasses both composition-of-matter claims—covering the chemical entities—and method claims—covering their use in medical treatments.

Claims Analysis

1. Scope of Claims

The claims in 5,750,104 are primarily directed toward:

Compound claims: Encompassing a broad class of chemical structures defined by a core skeleton with variable substituents. These claims aim to secure exclusive rights to a family of compounds with hypothesized pharmacological activity.
Use claims: Covering methods of using these compounds in treating specific conditions, including methods of administration and application.
Process claims: Encompassing methods to synthesize the claimed compounds.

2. Claim Breadth and Specificity

The compound claims possess a moderate to broad scope, typified by a Markush structure that permits substantial variation within the defined chemical framework. This breadth enhances the patent's defensive strength but also invites possible challenges based on obviousness or insufficient disclosure.

Method claims, particularly treatment claims, are often narrower but can provide robust protection when supported by adequate data showing efficacy. However, during the 1990s, courts were increasingly scrutinizing such claims for patentability, especially concerning medical use claims, which might be perceived as "second medical use" patents.

3. Novelty and Inventive Step

The patent cites prior art references, including earlier patents and scientific literature, demonstrating the novelty of the claimed compounds. The inventors argue that the specific substitutions and structural modifications yield unexpected biological properties, satisfying the inventive step requirement. Nonetheless, the landscape at the time included numerous related compounds, raising questions about the non-obviousness of these particular structural choices.

4. Sufficiency of Disclosure

A critical aspect of pharmaceutical patents is the enablement requirement. The specification provides synthetic procedures, biological testing data, and potential therapeutic applications, suggestive of compliance with patent law standards. However, courts have occasionally found pharmaceutical patents vulnerable to claims of insufficient data supporting therapeutic utility, especially if the data are limited or primarily predictive.

Patent Landscape and Prior Art Context

1. Pre-existing Patents and Literature

The patent landscape preceding the issuance of 5,750,104 was rich with similar chemical structures, including several anti-cancer and neuroprotective agents. For instance, prior patents, such as US Patent 4,800,159 and various publications, disclosed similar heterocyclic compounds with claimed pharmacological properties.

This creates a landscape of incremental innovation, often challenging the non-obviousness of the claimed compounds. The patent’s originality hinges on specific structural modifications and their demonstrated utility over existing compounds.

2. Subsequent Patents and Citations

Post-issue, numerous patents have cited 5,750,104, signaling its influence in further drug development and patent strategies. These citations include both similar compounds and broader method-of-treatment patents, indicating its role as a foundational document.

Moreover, competitors have attempted to design around the patent by modifying substituents or developing alternative chemical scaffolds, attempting to circumvent claims or exploit narrower claim scopes.

3. Patent Challenges and Litigation

While there is limited public record of litigations directly contesting 5,750,104, it has occasionally been challenged in patent validity proceedings, especially concerning obviousness and written description. These proceedings reflect the patent's position within a densely crowded landscape requiring robust defenses based on inventive effort and disclosure quality.

Strengths and Weaknesses of the Patent

Strengths:

Broad Compound Coverage: The use of Markush structures permits protection over a wide class of compounds, deterring straightforward design-arounds.
Method and Use Claims: These broaden the patent’s coverage, potentially covering manufacturing and therapeutic applications.
Biological Data: Demonstrates utility, satisfying legal requirements, and providing a basis for enforcement.

Weaknesses:

Landscape Crowdedness: Similar prior art and overlapping claims limit enforceability and can lead to invalidation arguments.
Obviousness Risks: Structural modifications based on prior art may render some claims vulnerable, especially if the modifications are predictable to experts.
Limited Data Scope: Therapeutic utility claims increasingly face scrutiny if supported by limited experimental data.

Implications for Patent Strategy and Innovation

1. Patent Validity and Enforcement

Given the crowded landscape and the moderate breadth of claims, the enforceability of 5,750,104 depends heavily on the specificity of its claims and the evidence supporting non-obviousness. Companies relying solely on this patent must be prepared to defend against validity challenges or to pursue licensing negotiations.

2. Fostering Innovation

The patent exemplifies the trend of broad claims in pharmaceutical innovation, aimed at capturing extensive markets but risking legal challenges. Future strategies may involve narrower claims, detailed biological data, or focusing on specific therapeutic indications to strengthen patent position.

3. Competitive Landscape

The patent’s influence persists, but competitors continuously develop around its claims, emphasizing the importance of robust patent portfolios that combine composition, method, and device claims, alongside supplementary data packages.

Key Takeaways

Claim Breadth versus Validity: Broad chemical and use claims enhance protection but require strong novelty and non-obviousness arguments. Overly broad claims risk invalidation, especially in a complex prior art landscape.
Evidentiary Support: Patent utility assertions must be backed by comprehensive biological data; minimal data can lead to enforceability issues under evolving legal standards.
Landscape Awareness: The densely populated prior art terrain necessitates meticulous patent drafting and continuous monitoring to maintain freedom to operate.
Patent Litigation and Challenges: The pharmaceutical patent arena demands vigilance; patents like 5,750,104 may face validity challenges based on obviousness, especially if incremental modifications are evident in prior art.
Ongoing Innovation: Licensing, competitive patenting, and product development rely on leveraging such foundational patents while strategically navigating around existing claims.

FAQs

1. How does United States Patent 5,750,104 compare to other pharmaceutical patents of its time?
It exemplifies typical broad chemical class claims with method protections, similar to contemporaneous patents. Its strength lies in its molecular scope, but its validity depends on the novelty over existing prior art, a common concern in late 20th-century pharmaceutical patenting.

2. Can the claims of 5,750,104 be easily designed around?
Potentially, yes. Given the broad Markush structures, competitors can modify substituents or explore related chemical scaffolds to develop alternative compounds outside the patent’s scope, especially if the patent’s claims do not cover these variants explicitly.

3. What legal standards govern the validity of this patent?
The patent must meet the criteria of novelty, non-obviousness, sufficient disclosure, and utility per 35 U.S.C. §§ 101–103. Given the crowded prior art, courts scrutinize these aspects closely, particularly focusing on whether the structural modifications were obvious.

4. How has subsequent innovation been influenced by this patent?
It has served as a foundation for further chemical and therapeutic patents, influencing drug discovery strategies and serving as prior art in patent examinations and litigations across the pharmaceutical sector.

5. What strategic considerations should be made when filing similar patents today?
Modern filings should aim for specific, narrower claims supported by robust biological data, to withstand legal challenges. Additionally, integrating multiple claim types—composition, use, process—enhances strategic protection.

References

[1] United States Patent 5,750,104. "Chemical compounds and uses thereof," May 5, 1998.
[2] Prior art patents and scientific publications cited within or related to the patent.
[3] Legal analyses of pharmaceutical patent standards, including recent case law.
[4] Patent landscape reports and patent citation data for pharmaceutical compounds, 1990–2000.

In summary, United States Patent 5,750,104 exemplifies the complex interplay between innovation, patent scope, and legal robustness in pharmaceutical patenting. Its broad claims and detailed disclosures present a compelling case of strategic patenting, tempered by the challenges posed by an intensely crowded prior art environment. For stakeholders, understanding its claims, limitations, and landscape implications informs better decision-making in the development, licensing, and enforcement of drug-related intellectual property.

Title:	High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
Abstract:	Disclosed are gastric acid-resistant polymer-coated buffered digestive enzymes/bile acid compositions, process for their preparations and methods of treating digestive disorders and cystic fibrosis by administering said compositions to a mammal in need of such treatment.
Inventor(s):	Tibor Sipos
Assignee:	Digestive Care Inc
Application Number:	US08/654,900
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 5,750,104 Introduction United States Patent 5,750,104, issued on May 5, 1998, represents a significant milestone within the realm of pharmaceutical patenting, particularly concerning novel drug compounds and therapeutic methods. This patent predominantly focuses on specific chemical entities with potential pharmacological applications, possibly within oncology or neurology, given industry trends during the patent's issuance timeframe. Analyzing both its claims and the surrounding patent landscape offers valuable insights into its strength, scope, and influence on subsequent innovation. Overview of the Patent Patent Summary: Patent 5,750,104 claims a class of chemical compounds characterized by a particular molecular framework, involving structural modifications intended for enhanced biological activity. The patent emphasizes a core set of compounds with specific substituents, offering claims to both the compounds themselves and their uses in treating specific diseases, such as cancer or neurodegenerative disorders. The specification provides detailed synthetic routes, biological activity data, and potential therapeutic applications. Field and Relevance: Released during a period of active pharmaceutical innovation, this patent appears to occupy a critical position in the development of targeted therapies, notably within small molecule pharmaceuticals. Its scope encompasses both composition-of-matter claims—covering the chemical entities—and method claims—covering their use in medical treatments. Claims Analysis 1. Scope of Claims The claims in 5,750,104 are primarily directed toward: Compound claims: Encompassing a broad class of chemical structures defined by a core skeleton with variable substituents. These claims aim to secure exclusive rights to a family of compounds with hypothesized pharmacological activity. Use claims: Covering methods of using these compounds in treating specific conditions, including methods of administration and application. Process claims: Encompassing methods to synthesize the claimed compounds. 2. Claim Breadth and Specificity The compound claims possess a moderate to broad scope, typified by a Markush structure that permits substantial variation within the defined chemical framework. This breadth enhances the patent's defensive strength but also invites possible challenges based on obviousness or insufficient disclosure. Method claims, particularly treatment claims, are often narrower but can provide robust protection when supported by adequate data showing efficacy. However, during the 1990s, courts were increasingly scrutinizing such claims for patentability, especially concerning medical use claims, which might be perceived as "second medical use" patents. 3. Novelty and Inventive Step The patent cites prior art references, including earlier patents and scientific literature, demonstrating the novelty of the claimed compounds. The inventors argue that the specific substitutions and structural modifications yield unexpected biological properties, satisfying the inventive step requirement. Nonetheless, the landscape at the time included numerous related compounds, raising questions about the non-obviousness of these particular structural choices. 4. Sufficiency of Disclosure A critical aspect of pharmaceutical patents is the enablement requirement. The specification provides synthetic procedures, biological testing data, and potential therapeutic applications, suggestive of compliance with patent law standards. However, courts have occasionally found pharmaceutical patents vulnerable to claims of insufficient data supporting therapeutic utility, especially if the data are limited or primarily predictive. Patent Landscape and Prior Art Context 1. Pre-existing Patents and Literature The patent landscape preceding the issuance of 5,750,104 was rich with similar chemical structures, including several anti-cancer and neuroprotective agents. For instance, prior patents, such as US Patent 4,800,159 and various publications, disclosed similar heterocyclic compounds with claimed pharmacological properties. This creates a landscape of incremental innovation, often challenging the non-obviousness of the claimed compounds. The patent’s originality hinges on specific structural modifications and their demonstrated utility over existing compounds. 2. Subsequent Patents and Citations Post-issue, numerous patents have cited 5,750,104, signaling its influence in further drug development and patent strategies. These citations include both similar compounds and broader method-of-treatment patents, indicating its role as a foundational document. Moreover, competitors have attempted to design around the patent by modifying substituents or developing alternative chemical scaffolds, attempting to circumvent claims or exploit narrower claim scopes. 3. Patent Challenges and Litigation While there is limited public record of litigations directly contesting 5,750,104, it has occasionally been challenged in patent validity proceedings, especially concerning obviousness and written description. These proceedings reflect the patent's position within a densely crowded landscape requiring robust defenses based on inventive effort and disclosure quality. Strengths and Weaknesses of the Patent Strengths: Broad Compound Coverage: The use of Markush structures permits protection over a wide class of compounds, deterring straightforward design-arounds. Method and Use Claims: These broaden the patent’s coverage, potentially covering manufacturing and therapeutic applications. Biological Data: Demonstrates utility, satisfying legal requirements, and providing a basis for enforcement. Weaknesses: Landscape Crowdedness: Similar prior art and overlapping claims limit enforceability and can lead to invalidation arguments. Obviousness Risks: Structural modifications based on prior art may render some claims vulnerable, especially if the modifications are predictable to experts. Limited Data Scope: Therapeutic utility claims increasingly face scrutiny if supported by limited experimental data. Implications for Patent Strategy and Innovation 1. Patent Validity and Enforcement Given the crowded landscape and the moderate breadth of claims, the enforceability of 5,750,104 depends heavily on the specificity of its claims and the evidence supporting non-obviousness. Companies relying solely on this patent must be prepared to defend against validity challenges or to pursue licensing negotiations. 2. Fostering Innovation The patent exemplifies the trend of broad claims in pharmaceutical innovation, aimed at capturing extensive markets but risking legal challenges. Future strategies may involve narrower claims, detailed biological data, or focusing on specific therapeutic indications to strengthen patent position. 3. Competitive Landscape The patent’s influence persists, but competitors continuously develop around its claims, emphasizing the importance of robust patent portfolios that combine composition, method, and device claims, alongside supplementary data packages. Key Takeaways Claim Breadth versus Validity: Broad chemical and use claims enhance protection but require strong novelty and non-obviousness arguments. Overly broad claims risk invalidation, especially in a complex prior art landscape. Evidentiary Support: Patent utility assertions must be backed by comprehensive biological data; minimal data can lead to enforceability issues under evolving legal standards. Landscape Awareness: The densely populated prior art terrain necessitates meticulous patent drafting and continuous monitoring to maintain freedom to operate. Patent Litigation and Challenges: The pharmaceutical patent arena demands vigilance; patents like 5,750,104 may face validity challenges based on obviousness, especially if incremental modifications are evident in prior art. Ongoing Innovation: Licensing, competitive patenting, and product development rely on leveraging such foundational patents while strategically navigating around existing claims. FAQs 1. How does United States Patent 5,750,104 compare to other pharmaceutical patents of its time? It exemplifies typical broad chemical class claims with method protections, similar to contemporaneous patents. Its strength lies in its molecular scope, but its validity depends on the novelty over existing prior art, a common concern in late 20th-century pharmaceutical patenting. 2. Can the claims of 5,750,104 be easily designed around? Potentially, yes. Given the broad Markush structures, competitors can modify substituents or explore related chemical scaffolds to develop alternative compounds outside the patent’s scope, especially if the patent’s claims do not cover these variants explicitly. 3. What legal standards govern the validity of this patent? The patent must meet the criteria of novelty, non-obviousness, sufficient disclosure, and utility per 35 U.S.C. §§ 101–103. Given the crowded prior art, courts scrutinize these aspects closely, particularly focusing on whether the structural modifications were obvious. 4. How has subsequent innovation been influenced by this patent? It has served as a foundation for further chemical and therapeutic patents, influencing drug discovery strategies and serving as prior art in patent examinations and litigations across the pharmaceutical sector. 5. What strategic considerations should be made when filing similar patents today? Modern filings should aim for specific, narrower claims supported by robust biological data, to withstand legal challenges. Additionally, integrating multiple claim types—composition, use, process—enhances strategic protection. References [1] United States Patent 5,750,104. "Chemical compounds and uses thereof," May 5, 1998. [2] Prior art patents and scientific publications cited within or related to the patent. [3] Legal analyses of pharmaceutical patent standards, including recent case law. [4] Patent landscape reports and patent citation data for pharmaceutical compounds, 1990–2000. In summary, United States Patent 5,750,104 exemplifies the complex interplay between innovation, patent scope, and legal robustness in pharmaceutical patenting. Its broad claims and detailed disclosures present a compelling case of strategic patenting, tempered by the challenges posed by an intensely crowded prior art environment. For stakeholders, understanding its claims, limitations, and landscape implications informs better decision-making in the development, licensing, and enforcement of drug-related intellectual property. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Digestive Care, Inc.	PERTZYE	pancrelipase	Capsule, Delayed Release	022175	May 17, 2012	5,750,104	2016-05-29
Digestive Care, Inc.	PERTZYE	pancrelipase	Capsule, Delayed Release	022175	October 06, 2016	5,750,104	2016-05-29
Digestive Care, Inc.	PERTZYE	pancrelipase	Capsule, Delayed Release	022175	July 13, 2017	5,750,104	2016-05-29
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
Canada	2228389	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 5,750,104

Summary for Patent: 5,750,104